Ascendra Balloon Aortic Valvaloplasty Catheter
K142199 · Edwards Lifesciences · OZT · Oct 29, 2014 · Cardiovascular
Device Facts
| Record ID | K142199 |
| Device Name | Ascendra Balloon Aortic Valvaloplasty Catheter |
| Applicant | Edwards Lifesciences |
| Product Code | OZT · Cardiovascular |
| Decision Date | Oct 29, 2014 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.1255 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Ascendra Balloon Aortic Valvuloplasty Catheter is indicated for balloon aortic valvuloplasty.
Device Story
The Ascendra Balloon Aortic Valvuloplasty Catheter is a sterile, single-use coaxial polyamide catheter featuring a distal inflatable polyamide balloon. It is used by physicians in clinical settings to dilate stenotic aortic valves prior to bioprosthesis implantation. The device is compatible with 0.035" guidewires and 14F sheaths. During operation, the catheter is positioned using two radiopaque marker bands; the balloon is then inflated via a proximal 'Y' connector using a diluted contrast medium solution injected through an inflation device. This mechanical dilation prepares the valve site for subsequent transcatheter or surgical valve replacement. The device's design and function facilitate the valvuloplasty procedure, aiming to improve valve hemodynamics and procedural success for patients undergoing aortic valve replacement.
Clinical Evidence
Clinical assessment relied on literature review, comparison to marketed devices, and complaint analysis. The assessment concluded that balloon aortic valvuloplasty (BAV) for predilation is feasible and safe. Evidence was supported by clinical trial data from PMA P110021 and P130009, providing reasonable assurance of safety and effectiveness.
Technological Characteristics
Coaxial polyamide catheter with distal inflatable polyamide balloon. Features two radiopaque marker bands for placement. Compatible with 0.035" guidewire and 14F sheath. Sterilized via ethylene oxide. Biocompatibility per ISO 10993-1. Mechanical operation via contrast medium inflation.
Indications for Use
Indicated for balloon aortic valvuloplasty in patients requiring dilation of a stenotic aortic valve prior to bioprosthesis implantation.
Regulatory Classification
Identification
A balloon aortic valvuloplasty catheter is a catheter with a balloon at the distal end of the shaft, which is intended to treat stenosis in the aortic valve when the balloon is expanded.
Special Controls
*Classification.* Class II (special controls). The special controls for this device are:(1) The device must be demonstrated to be biocompatible.
(2) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components.
(3) Non-clinical performance evaluation must demonstrate that the device performs as intended under anticipated conditions of use, including device delivery, inflation, deflation, and removal.
(4) In vivo evaluation of the device must demonstrate device performance, including the ability of the device to treat aortic stenosis.
(5) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device.
In combination with the general controls of the FD&C Act, the NuMED NuCLEUS and NuCLEUS-X BAV Catheters are subject to the following special controls:
Predicate Devices
- Loma Vista Medical (BARD) TRUE Dilation Balloon Valvuloplasty Catheter (K121083)
- NuMed Z-MED and Z-MED II™ Balloon Aortic Valvuloplasty Catheter (K122012)
Related Devices
- K231814 — ValvuloPro Valvuloplasty Balloon Catheter · Dongguan TT Medical, Inc. · Oct 12, 2023
- DEN080015 — NUCLEUS-X PTV CATHETER · NuMED, Inc. · Jun 11, 2012
- K260437 — Valvuloplasty Balloon Catheter (ValvuloPro) · Dongguan TT Medical, Inc. · Mar 20, 2026
- K133569 — TRUE DILATATION BALLOON VALVULOPLASTY CATHETER, 20MM X 4.5 CM, 22MM X 4.5CM, 24 MM X 4.5CM, 26MM X 4.5CM · Bard Peripheral Vascular, Inc. · Dec 20, 2013
- K220881 — INOUE BALLOON A · Toray Industries, Inc. · Dec 18, 2022
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of a stylized caduceus, which is a staff with two snakes entwined around it, often used as a symbol of medicine and healthcare. The logo is presented in black and white.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 29, 2014
Edwards Lifesciences % Ms. Susan Reynolds Regulatory Affairs Principal Project Manager One Edwards Way Irvine, California 92614
Re: K142199
> Trade/Device Name: Ascendra Balloon Aortic Valvuloplasty Catheter Regulation Number: 21 CFR 870.1255 Regulation Name: Balloon Aortic Valvuloplasty Catheter Regulatory Class: Class II Product Code: OZT Dated: August 8, 2014 Received: August 11, 2014
Dear Ms. Susan Reynolds:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
{1}------------------------------------------------
Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
M.A. Hillebrand
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known)
Device Name
Ascendra Balloon Aortic Valvuloplasty Catheter
Indications for Use (Describe)
The Ascendra Balloon Aortic Valvuloplasty Catheter is indicated for balloon aortic valvuloplasty.
Type of Use (Select one or both, as applicable)
> Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
#### PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
#### FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
# 510(k) Summary
| Submitter: | Edwards Lifesciences, LLC<br>One Edwards Way<br>Irvine, CA 92614 |
|----------------------|-------------------------------------------------------------------------------------|
| Contact: | Susan Reynolds, Phone: 949-756-4518, Fax: 949-809-5655 |
| Prepared: | August 8, 2014 |
| Trade Name: | Ascendra Balloon Aortic Valvuloplasty Catheter |
| Common Name: | Balloon aortic valvuloplasty catheter |
| Classification: | Balloon aortic valvuloplasty catheter, 21 CFR 870.1255,<br>Product Code OZT |
| Predicate Device(s): | Loma Vista Medical (BARD) TRUE Dilation Balloon Valvuloplasty<br>Catheter (K121083) |
| | NuMed Z-MED and Z-MED II™ Balloon Aortic Valvuloplasty Catheter<br>(K122012) |
## Device Description:
The Edwards Ascendra Balloon Aortic Valvuloplasty Catheter is used for balloon aortic valvuloplasty. The device consists of a coaxial polyamide catheter with a distal inflatable polyamide balloon intended to dilate (perform valvuloplasty on) the stenotic aortic valve prior to implantation of a bioprosthesis. Two radiopaque marker bands indicate the dilating section of the balloon and aid in balloon placement. At the proximal end of the catheter, there is a standard "Y" connector for balloon inflation and a guidewire lumen. An inflation device may be connected directly or indirectly (using the supplied extension tubing) to the balloon inflation luer port of the catheter. The balloon is inflated by injecting a diluted contrast medium solution through the luer port (marked "BALLOON") on the "Y" connector. The device is supplied sterile for single use only. The BAVC is provided in a 20 mm size and is compatible with a 0.035" guidewire and a 14F sheath.
### Indications for Use:
The Ascendra Balloon Aortic Valvuloplasty Catheter is indicated for balloon aortic valvuloplasty.
### Comparison to Predicate:
The BAVC is substantially equivalent to Loma Vista Medical (BARD) TRUE Dilation Catheter, 510(k) No.: K121083 and the NuMed Z-MED and Z-MED II™ Balloon Aortic
{4}------------------------------------------------
Valvuloplasty Catheter, 510(k) No.: K122012 in intended use, design, technology and performance. The BAVC differs from the predicate devices in length.
# Summary of Non-Clinical Testing:
Non-clinical testing was completed to demonstrate that the Ascendra balloon aortic valvuloplasty catheter meets the established performance characteristics, and to verify that design requirements are satisfied. Testing included biocompatibility evaluation per ISO 10993-1, ethylene oxide sterilization validation, and package qualification. Device functional testing included surface/visual Inspection, dimensional inspection, radiopacity, balloon diameter, insertion force into sheath, balloon inflation time, balloon compliance, catheter kink test, balloon catheter retrieval force, balloon fatigue and burst, leakage test, bond testing. The conclusions drawn from the non-clinical tests demonstrated that the device is substantially equivalent to the predicate devices.
# Summary of Clinical Data:
Clinical assessment for the Ascendra balloon aortic Valvuloplasty catheter consisted of a literature review, comparison to currently marketed devices and complaint analysis. The assessment concluded that the use of BAV to predilate the aortic valve prior to TAVR or as a bridge to percutaneous or surgical aortic valve replacement is feasible and safe. This analysis, in combination with the results of the clinical trials reviewed as part of PMA P110021 and P130009, provides reasonable assurance that the Ascendra balloon aortic Valvuloplasty catheter is safe and effective for its indicated use.
# Conclusion:
The Edwards Catheter is substantially equivalent to the predicate devices, Loma Vista Medical (BARD) TRUE Dilation Catheter and the NuMed Z-MED and Z-MED II™ Balloon Aortic Valvuloplasty Catheter.